Detailed Project Report (DPR) on liquid manufacturing like syrups & suspension (pharma unit)

LIQUID MANUFACTURING LIKE SYRUPS & SUSPENSION (PHARMA UNIT) [3630]

The foundation of the modern Indian pharmaceutical Industry was laid at the start of the current century when in 1901, a small factory known as the Bengal Chemical & Pharmaceutical works was established in Kolkata. Though the two world Wars gave a Phillip to the development of industry, the progress made under British rule was not significant except the British introduced into this country the allopathic system of medicine. The country depended largely for its requirements on U.K., France and Germany. The development of Indian Drugs and pharmaceuticals Industry was not commensurate with the size of this country and the growing needs of people, when Indian embarked on its planned economic expansion industry has been substantial and many sides with the result that it has becomes one of the leading industries. India is now producing a larger quantity of varied pharmaceuticals products. In 1948, the sale of pharmaceuticals products. In 1948, the sale of pharmaceutical products amounted to just Rs. 100 million. By 1954 the figure had rised to Rs. 540 million and by 1960 to Rs. 700 million. The figure stood at between Rs. 1500 million in 1965 and Rs. 4000 millions in 1975, Rs. 12000 millions in 1980 and above Rs. 18,500 millions presently. The restrictions, however, continued on import of non essential patent and proprietory medicen for which suitable substitutes manufactured indigenously were available. Prior to the launching of the second plan the manufacture of pharmaceuticals was limited largely to the processing of bulk imported drugs into tablets, capsules and other formulations. Indian firms under agreement with foreign firms are making injectables, powders ointments and liquids, and were also filling antibiotics. Certain units were producing biological extracts, vacines, and syrup. Alkalods, like quinins stry-chinea, caffeine, and morphine were also being extracted. It was however obvious that the country could not forever be dependent on foreign manufacturers for both finished drugs and basis raw materials. With the changing political climate, pharmaceutical manufacturers in India were encouraged to take up the manufacture of basis drugs wherever it was economically possible and technically feasible. A system of collaboration was instituted, under which Indian manufacturers in association with established firms in U.S.A., Italy, U.K. began to produce a fairly comprehensive range of basic items. While the allocation of foreign exchange for the import of raw materials and basic intermediates for the production  of drugs, has been more or less static the  value  of products  manufactured has increased progressively  several  fold clearly  indicating  the  growing stature, of  industry and its capacity to switching over to basic raw materials and  components of  indigenous origin, and now the country is stated  to  achieve self,  sufficiency in synthetic drugs of the sulpha  group, anti T.B. drugs, Vitamins, and intermediates. It has, however, been found that the present installed capacity is insufficient to meet the over growing demand of the massive population and the scope for new units to come up is substantial.

COST ESTIMATION

Plant Capacity                   150000 Bottles/Day  
Land & Building (2200 sq.mt)     Rs. 1.76 Cr
Plant & Machinery                Rs. 90 Lac
Working Capital for 2 Months     Rs. 4.16 Cr
Total Capital Investment         Rs. 6.98 Cr
Rate of Return                   55%
Break Even Point                 33%


INTRODUCTION    
OVERVIEW OF INDIAN PHARMACEUTICALS INDUSTRY    
EXHIBIT 1 MULTIPLE DIGITAL AND ADVANCED ANALYTICS
APPLICATIONS IN PHARMA VALUE CHAIN    
INDIA MARKET DYNAMICS & IMPLICATIONS FOR INDIA PHARMA    
EXHIBIT 2 INCREMENTAL GROWTH IN THE INDIAN
PHARMACEUTICAL MARKET    
OPPORTUNITIES FOR INDIA AS A GLOBAL SUPPLY DESTINATION    
INSTITUTIONALIZING QUALITY AND COMPLIANCE EXCELLENCE    
EXHIBIT 3 OUTSTANDING QUALITY INVOLVES BUILDING QUALITY IN THE ORGANIZATION’S OPERATING SYSTEMS, MANAGEMENT SYSTEMS
AND PEOPLE SYSTEMS    
BUILDING OPERATIONAL EXCELLENCE    
ALTERNATE SOURCING AND SELF-SUFFICIENCY IN APIS/INTERMEDIATES    
MARKET POSITION OF PHARMACEUTICALS INDUSTRY    
A USD 55 BILLION MARKET BY 2020 WITH POTENTIAL FOR MORE    
MASS THERAPIES WILL REMAIN IMPORTANT EVEN THOUGH
SPECIALTY THERAPIES WILL INCREASE SHARE    
INCREASING INVESTMENTS IN THE SECTOR    
PRESENT MANUFACTURERS/SUPPLIERS    
FORMULATION OF COUGH SYRUP    
FORMULATION OF COUGH SYRUP (HERBAL)    
FORMULATION OF PARACETAMOL SYRUP    
FORMULATION OF PARACETEMOL SYRUP    
FORMULATION OF PHARMACEUTICAL SOLUTION FORM OF PARACETAMOL IN THE PEDIATRIC USE    
FORMULATION 1    
FORMULATION 2    
FORMULATION 3    
FORMULATION 4    
FORMULATION 5    
FORMULATION 6    
FORMULATION OF POLY HERBAL SYRUP (ANTI DIABETIC)    
STEPS IN MANUFACTURING PROCESS    
PREPARATION OF ACTIVE SOLUTION    
PREPARATION OF FLAVOR SOLUTION    
PREPARATION OF VEHICLE SOLUTION    
PREPARATION OF FINAL SYRUP    
COMPOSITION OF ANTICID SUSPENSION    
PROCESS FLOW DIAGRAM OF PHARMACEUTICAL SYRUP    
LIQUID MIXING & BLENDING    
BLENDING FOR CONSISTENCY    
METHODS OF PREPARATION OF SYRUPS    
1. SOLUTION WITH THE AID OF HEAT    
2. SOLUTION BY AGITATION WITHOUT THE AID OF HEAT    
3. ADDITION OF SUCROSE TO A MEDICATED LIQUID OR TO
   A FLAVORED LIQUID    
4. PERCOLATION    
PRESERVATION OF SYRUP    
PRODUCTION OF COUGH MIXTURES AND PHARMACEUTICAL SYRUPS    
STAGE 1    
STAGE 2    
STAGE 3    
OTHERS FORMULATIONS OF SYRUPS    
SYRUPS    
ANTI ALLERGIC COUGH SYRUP    
EDIATRIC SYRUP OF PARACETAMOL    
VICKS FORMULA 44 COUGH MIXTURE    
PARACETAMOL - VITAMINIC SYRUP    
MULTIVITIMAN SYRUP    
COUGH SYRUP    
LIQUIDS    
1. GENERAL TONIC (MULTI VITAMIN)    
2. SODIUM GLYCEROPHOSPHATE           
3. VITAMIN B COMPLEX WITH DIGESTIVE ENZYMES    
TONIC LIQUID    
DETAILED MANUFACTURING PROCESS OF SYRUP (LIQUID)    
FILTERATION    
BOTTLING    
FLOW DIAGRAM OF MIXING PLANT    
SUPPLIERS OF RAW MATERIALS    
SUPPLIERS OF PLANT AND MACHINERY    
DISTILLED WATER PLANT    
STORAGE VESSEL (STORAGE TANKS)    
INSTRUMENTATION & PROCESS CONTROL EQUIPMENTS    
LABORATORY EQUIPMENTS    

APPENDIX – A:

01.    PLANT ECONOMICS    
02.    LAND & BUILDING     
03.    PLANT AND MACHINERY    
04.    OTHER FIXED ASSESTS    
05.    FIXED CAPITAL    
06.    RAW MATERIAL    
07.    SALARY AND WAGES    
08.    UTILITIES AND OVERHEADS
09.    TOTAL WORKING CAPITAL    
10.    TOTAL CAPITAL INVESTMENT    
11.    COST OF PRODUCTION    
12.    TURN OVER/ANNUM    
13.    BREAK EVEN POINT     
14.    RESOURCES FOR FINANCE    
15.    INSTALMENT PAYABLE IN 5 YEARS    
16.    DEPRECIATION CHART FOR 5 YEARS    
17.    PROFIT ANALYSIS FOR 5 YEARS    
18.    PROJECTED BALANCE SHEET FOR (5 YEARS)